2 promoters of Laurus Labs sell 70 lakh equity shares

Published On 2021-03-05 09:23 GMT   |   Update On 2021-03-05 10:20 GMT

Hyderabad: Laurus Labs Ltd. has recently announced that Dr.Satyanarayana Chava, Founder Promoter, CEO & ED, sold 52 lakh equity shares of the Company in the stock market at an average price of INR.368.59, per share, aggregating to INR 191.67 Crores and Mrs. Nagarani Chava, one of the promoters of the company sold 18 Lakh equity shares of the Company at an average price of 366.91 per...

Login or Register to read the full article

Hyderabad: Laurus Labs Ltd. has recently announced that Dr.Satyanarayana Chava, Founder Promoter, CEO & ED, sold 52 lakh equity shares of the Company in the stock market at an average price of INR.368.59, per share, aggregating to INR 191.67 Crores and Mrs. Nagarani Chava, one of the promoters of the company sold 18 Lakh equity shares of the Company at an average price of 366.91 per share at an aggregate value of INR 66.04 Crores, together 1.3% of the paid up capital of the Company.

Significant part of the above amount shall be utilized to release the pledge on their equity shares of the Company.

It may be recalled that the above promoters have purchased around 3% of the then paid up capital of the Company in the year 2018.

Read also: Laurus Labs bags Golden Peacock Award for Excellence in Corporate Governance 2020

Laurus Labs is an Indian pharmaceutical company headquartered in Hyderabad.

The Company's major focus areas include anti-retroviral, Hepatitis C and Oncology drugs.

Most of the Laurus Labs manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA, etc.



Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News